cyrilzakka/clinical-trials huggingface dataset:
Effects of Motivating People With Schizophrenia to Exercise

This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their participation in a walking program.

Schizophrenia is a chronic brain disorder that affects about 1% of Americans. People with schizophrenia experience extreme paranoia, often claiming that they hear voices not heard by others and that others are invading or controlling their minds with the intent to hurt them. More specific symptoms include hallucinations, delusional behaviors, disordered movements, and decreased ability to comprehend and apply information to everyday activities. The severity of these symptoms makes self-care and regular exercise difficult for people with schizophrenia. The fatality rate from diabetes, heart disease, and other obesity-related illnesses is significantly higher in people with schizophrenia. Exercise is known to reduce health problems associated with obesity, yet few studies have encouraged exercise as a treatment method for improving the health of those with schizophrenia. Furthermore, the long-term physical and mental effects of consistent exercise on people with schizophrenia are not well-known. This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their attendance, persistence, and compliance to a walking program.

Participants in this study will be randomly assigned to one of two groups. Both groups will continue their regular medications and treatments throughout the study. Upon entry, members of both groups will complete the same two forms concerning attitudes toward exercise. Group 1 participants will attend weekly 1-hour exercise information sessions for 4 weeks. Group 2 participants will attend weekly 1-hour general health information sessions for the same 4 weeks. Participants of both groups will then take part in identical 16-week walking programs. The walking program will consist of three 30- to 50-minute walks per week, including 10 minutes of warm up and 10 minutes of cool down stretching. All participants will gradually increase their walking time from 5 minutes to 30 minutes during the program. At the completion of the walking programs, participants of both groups will complete repeat forms about their attitudes toward exercise. There will be no follow-up visits for the participants.

Eligibility Criteria:
Inclusion Criteria:

* Meets DSM-IV criteria for schizophrenia
* Speaks English
* Stable medication regimen
* Able to receive medical clearance for moderate exercise

Exclusion Criteria:

* Hospitalized within 1 year of study entry for angina, heart attack, or cardiac surgery
* Diagnosed with congestive heart failure
* Has a pacemaker
* Heart rate less than 50 bpm or more than 100 bpm at rest
* Uncontrolled hypertension
* History of spinal or hip fracture
* Unable to walk or move around without assistance
* Any other medical condition, in the opinion of primary care provider, that would prevent safe participation in the study
Sleep Disruption Pattern - Epilepsy Monitoring Unit

Epilepsy affects millions worldwide, with 40% of patients experiencing uncontrolled seizures despite medication. Comprehensive epilepsy centers recommend continuous video-electroencephalography monitoring to define seizure type and distinguish mimickers. This process, however, is resource-intensive, with lengthy hospital stays. The investigators' recent study identified a heightened association between arousals and epileptic activity in drug-resistant focal epilepsy patients. Building on these findings, the investigators aim to explore whether disrupting sleep with an alarm system triggers earlier occurrence of seizures, potentially offering insights to reduce hospital stay durations in epilepsy monitoring units.


Eligibility Criteria:
Inclusion Criteria:

* Age 14 to 60 years
* EMU monitoring for presurgical evaluations
* Average 2-3 seizures per week based on pre-admission seizure diary
* Sleep as a known seizure trigger

Exclusion Criteria:

- Multiple seizures a day based on pre-admission seizure diary
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

Patients experiencing a mild heart attack will receive one of two medications which thin the blood to discern which is superior.


Eligibility Criteria:
Inclusion Criteria

* Male or nonpregnant female greater than or equal to 18 years old
* Ischemic pain originating or persisting at rest, or its clinical equivalent, lasting greater than or equal to 10 minutes and occurring within the 24 hours before enrollment
* At least 2 of the following:

  * ECG changes: New or presumably new ST-segment depression greater than or equal to 0.1 mV (greater than or equal to 1 mm), or transient (\<30 minutes) ST-segment elevation greater than or equal to 0.1 mV (greater than or equal to 1 mm) in at least 2 contiguous leads
  * Abnormal cardiac enzymes within the 24 hours before enrollment, defined as elevated troponin I or T greater than the established criteria at each site OR creatine kinase CK-MB level greater than the site's upper limit of normal
  * Age greater than or equal to 60 years

Exclusion Criteria:

* Known or suspected pregnancy
* Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including bypass surgery); active bleeding
* Impaired hemostasis: known International Normalized Ratio (INR) \>1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/mL), or history of thrombocytopenia with GP IIb/IIIa inhibitor therapy, heparin, or enoxaparin
* Angina from a secondary cause such as severe, uncontrolled hypertension (systolic blood pressure \>180 mm Hg despite treatment); anemia; valvular disease; congenital heart disease; hypertrophic cardiomyopathy; restrictive or constrictive cardiomyopathy; thyrotoxicosis
* PCI within the past 24 hours, not including coronary angiography only
* Allergy to pork or pork products
* Contraindications to UFH or LMWH
* Recent (\<48 hours) or planned spinal/epidural anesthesia or puncture
* Thrombolytic therapy within the preceding 24 hours
* Other serious diseases, including severe liver disease or renal failure \[creatinine clearance \<30 mL/min
* Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrollment in this trial
* Inability to give informed consent or high likelihood of being unavailable for follow-up
* Not a candidate for intervention, (angiography or PCI)
* Treatment with a direct thrombin inhibitor or a low molecular weight heparin other than enoxaparin in the 7 days preceding enrollment.
Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected organs are usually the skin, bone marrow, lymph nodes and the central nervous system. Patients with BPDCN have poor outcomes with median overall survival (OS) ranging in the largest series of patients from 8 to 12 months.

Patient care must be defined in this pathology. Despite 40%-90% complete remission (CR) rates after initial chemotherapy, relapses are almost inevitable.

The investigators have developed a national network to collect clinical and biological data of French patients diagnosed with BPDCN.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) from January 2000 to June 2013 in France.
* Diagnosis should be established by hematology laboratory of French blood Agency of Bourgogne Franche-Comté and/or by anatomopathological analysis (realized in local centres or by Tony Petrella at Dijon University Hospital) according to phenotypic and anatomopathological criteria published in the literature.

Exclusion Criteria:

* No exclusion criteria
A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.


Eligibility Criteria:
Inclusion criteria:

* Participant will have reached the legal age by the time of entrance into the run-in period.
* Participant has no active medical problem, other than essential hypertension,

which might of itself or by this treatment significantly affect the Participant's blood pressure.

- Participants diagnosed with mild to moderate essential hypertension or

hypertension accompanying with established cardiovascular (CV) and renal diseases who are receiving antihypertensive regimen (exclude diuretic), yet not attaining to treatment goal\*.

\* Note: For essential hypertension, the goal is to reduce the blood pressure to less than 140/90. For hypertension with established CV and renal diseases, the BP goal is \< 130/80. (According to 2007 European Society of Hypertension (ESH) - European Society of Cardiology (ESC) guideline)

* Participant is either receiving antihypertensive therapy or no treatment.
* Participants with stable diabetes mellitus may enter the study.

Exclusion criteria:

* Pregnant or lactating females.
* Secondary hypertension of any etiology (such as unilateral or bilateral renal

disease, renal artery stenosis, coarctation of the aorta, pheochromocytoma).

* History of malignant hypertension.
* Sitting systolic blood pressure \>210 mmHg at Visit 1 (Day 0).
* Participants with unresolved cerebrovascular accident or transient ischemic attack in the acute stage at visit 1.
* A clinically confirmed myocardial infarction within the recent 3 months.
* Angina pectoris.
* Clinically important cardiac arrhythmia.
* History of unexplained syncope within the prior 2 years, or a known syncopal

disorder.

- Presence of hemodynamically significant obstructive valvular disease of

cardiomyopathy.

* Percutaneous coronary angioplasty or coronary artery bypass surgery within the prior 3 months of visit 1.
* Participant with a single functioning kidney.
Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee

Medical condition under investigation: Osteoarthritis of the hip or knee

Number of patients planned: 480 adult patients

Main objective: To evaluate and compare the tolerability profile of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients with painful osteoarthritis of the hip or knee

Secondary objectives: To compare the overall efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients suffering from different complaints due to painful osteoarthritis of the hip or knee


Eligibility Criteria:
Inclusion Criteria:

* male or female patients aged between 18 and 75 years
* everyday joint pain for the past three months
* global pain intensity in the involved joint (hip or knee) of "moderate" to "severe" within the last 48 h

Exclusion Criteria:

* acute inflammation or ischaemic necrosis
* paget's disease, chondrocalcinosis, ochronosis of the hip/knee joint
* slowly progressing hip/knee arthropathy in particular of tuberculosis aetiology
* hip/knee arthropathy due to diabetes mellitus
* Charcot's joint
* villous synovitis
* chondromatosis of the synovium
* patients with existing gastritis or existing ulcers or bleedings in the gastrointestinal tract or patients with history of gastrointestinal ulcers or gastrointestinal haemorrhage in the past 6 months
Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study

The purpose of this study is to evaluate the diagnostic performance and safety of ascending doses of mercury, aluminum and palladium metal allergens proposed for inclusion in a metal allergen panel. Optimal dose will be selected based on the lowest dose of each allergen eliciting a positive response in 70-90% of subjects tested.

This is a single-center, double-blind, randomized study to compare the diagnostic performance (primary) and safety (secondary) of ascending doses of mercury, aluminum and palladium in 20 adult subjects who have a clinical history of contact dermatitis and have had a past positive patch test to one of the allergens on this study. Investigators and subjects will be blinded to the exact location of each dose within the allergen panel but will not be blinded to the allergen being tested, nor the range of allergen doses within each panel.

Eligibility Criteria:
Inclusion Criteria:

1.15 years of age or older.

2. History of contact dermatitis.

3. Positive patch results to 1) mercury (elemental), 2) aluminum (aluminum chloride hexahydrate, aluminum hydroxide and/or aluminum lactate) or 3) palladium (sodium tetrachloropalladate and/or palladium chloride) within the past 10 years.

4. Male or non-pregnant non-lactating female. Female subjects must state, at visit one that they are not pregnant, not lactating nor are they intending to become pregnant for the course of the study.

5. Has understood and signed the approved Informed Consent/Assent Form, which is consistent with all institutional, local and national regulations. Assent Form for all minor subjects (ages 15-17) must be signed by the guardian/parent.

Exclusion Criteria:

1. Breastfeeding or pregnant or intending to become pregnant for the course of the study.
2. Topical treatment with corticosteroids or other immunosuppressive agents on or near the test area during the 7 days prior to inclusion in this study.
3. Systemic treatment with corticosteroids (equivalent to \> 10 mg prednisone) or other immunosuppressive agents during the 7 days prior to inclusion in this study. Inhaled treatments are permitted.
4. Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to inclusion in this study.
5. Acute dermatitis outbreak or dermatitis on or near the test area on the back.
6. Inability to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity).
7. Participation in a clinical trial of an investigational drug, treatment or device other than T.R.U.E. TEST during this study or 3 weeks prior to inclusion in this study.
8. An opinion of the Investigator that deems the potential subject to be non-compliant, unable to return for study visits or complete the study as detailed in the protocol.
Point-of-Care Testing in Coagulopathic Patients Undergoing Cardiac Surgery - a Multicenter Study

Recently, the investigators study group showed in a mono center study that Point of Care (POC) based hemotherapy may reduce transfusion rates of allogenic blood products in perioperative care of coagulopathic cardiac surgery patients. The investigators aim to verify the obtained results by conducting this multicenter study.


Eligibility Criteria:
Inclusion Criteria:

Step 1:

* Patients scheduled for elective, complex cardiothoracic surgery (combined coronary artery bypass graft and valve surgery, double or triple valve procedures, aortic surgery or redo surgery) with cardiopulmonary bypass (CPB)

Step 2:

* diffuse bleeding after heparin reversal following extracorporeal circulation or
* intra- or postoperative blood loss exceeding 250 ml/h or 50 ml/10 min

Exclusion Criteria:

* Pregnancy
20K Distributed Learning Challenge

Machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.

All current innovations in medicine, including personalized medicine; artificial intelligence; (Big) data driven medicine; learning health care system; value based health care and decision support systems, rely on the sharing of data across health care providers. But sharing of data is hampered by administrative, political, ethical and technical barriers(Sullivan et al., 2011). This limits the amount of health data available for the above innovations and life sciences in general as well as other secondary uses such as quality improvement.

The investigators hypothesize that sharing questions rather than sharing data is a better approach and can unlock orders of magnitude more data while limiting privacy and other concerns. An infrastructure to bring questions to the data has been demonstrated to work recently in project such as euroCAT(Lambin et al., 2013; Deist et al., 2017), Datashield (Gaye et al., 2014) and OHDSI (Hripcsak et al., 2015). However, the scale of the prior work has been limited in terms of the number of data subjects, number of data providers and global coverage.

In the experience of the investigators, the main challenges of scaling up the infrastructure are 1) the effort necessary to make data FAIR at each site ("stations"), 2) the technical and legal governance ("track") and 3) the mathematics and engineering of learning applications ("trains") - together called the Personal Health Train (PHT) infrastructure. Since multiple years a global consortium of healthcare providers, scientists and commercial parties called CORAL (Community in Oncology for RApid Learning) have worked on all three PHT challenges.

The aim of this study is to show that the PHT distributed learning infrastructure can be scaled to many 1000s of patients, specifically the investigators aim to machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.

Eligibility Criteria:
Inclusion Criteria:

* Non small cell lung cancer
* Treated in one of the participating hospitals

Exclusion Criteria:

* No non small cell lung cancer
* Not treated in one of the participating centers
Applying Novel Technologies and Methods to Self-Regulation: Behavior Change Tools for Smoking and Binge Eating

This study will evaluate the extent to which we can engage and manipulate putative targets within the self-regulation domain within and outside of laboratory settings in samples of smokers and overweight/obese individuals with binge eating disorder. This is the fourth phase of a study that aims to identify putative mechanisms of behavior change to develop an overarching "ontology" of self-regulatory processes.


Eligibility Criteria:
Inclusion Criteria:

* Understand English sufficiently to provide informed consent
* Right-handed
* Normal or corrected-to-normal vision and no color blindness
* Interest in engaging with Laddr to modify self-regulatory behavior

Additional Inclusion Criteria for Smoking sample:

* Smoke 5 or more tobacco cigarettes/day for past year
* BMI greater than or equal to 17 and less than 27

Additional Inclusion Criteria for Binge Eating Sample:

* BMI greater than or equal to 27 and less than 45
* Weight limit of 350 lbs
* Non-smoking (defined as no cigarettes in past 12 months-this includes former and never smokers)

Exclusion Criteria:

* Significant medical illness
* History of mental disorder due to a medical condition
* Lifetime history of major psychotic disorders (including schizophrenia and bipolar disorder)
* Current use of any medication for psychiatric reasons (including stimulants and mood stabilizers)

Additional Exclusion criteria for Binge Eating Sample:

* Lost weight in recent past (\>10 pounds in past 6 months)
* Currently in a weight-loss program (e.g., Weight Watchers, Jenny Craig)
* Currently on a special diet for a serious health condition
* Current engagement in psychotherapy for binge eating disorder

Additional Exclusion Criteria for Smoking Sample:

* Binge eating behavior
* Current engagement in psychotherapy for smoking behavior
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.

Part 1 is a randomized, double-maskedtrial trial designed to investigate the use of TLC399 in subjects with macular edema due to CRVO or BRVO. Three different dose strengths will be evaluated.

Part 2 is a randomized, double-masked study designed to evaluate 2 doses of TLC399 in subjects with macular edema due to CRVO or BRVO. Subjects will be randomized 1:1 to receive two different dose strenghs of investigational product.

Eligibility Criteria:
Inclusion Criteria:

1. male or female, at least 18 years of age
2. macular edema due to CRVO or BRVO
3. best-corrected visual acuity (BCVA) score of 20/40 to 20/400
4. mean central subfield thickness (CST) ≥350 um
5. willing and able to comply with the study procedure and sign a written informed consent
6. agree to use a medically acceptable form of birth control

Exclusion Criteria:

1. poorly controlled diabetes
2. history of significant intraocular pressure (IOP) elevation to steroid treatment
3. history of ocular hypertension and glaucoma
4. cataract surgery in the study eye within 3 months, or intraocular surgery within 6 months prior to screening
5. use of hemodilution for the treatment of RVO
6. use of IVT ranibizumab or bevacizumab in the study eye within 6 weeks prior to screening; or IVT aflibercept within 8 weeks prior to screening
7. IVT Ozurdex to the study eye within 6 months prior to screening
8. prior use of Retisert or Iluvien
9. use of systemic steroids or heparin within 1 month prior to screening
Semen Analysis After Proton Therapy for Prostate Cancer

The purpose of this study is to evaluate semen for changes following treatment with proton radiation therapy.


Eligibility Criteria:
Inclusion Criteria:

- Diagnosis of low to intermediate risk prostate cancer and elected to have proton radiation therapy at University of Florida Proton Therapy Institute (UFPTI).

Exclusion Criteria:

* Current use of Flomax, Hytrin, Cardura, Uroxatral, or Rapaflo.
* History of vasectomy.
* Current use of Lupron, Zoladex, Trelstar, Casodex, Eulexin.
* Current use of Avodart or Proscar.
Creative Drama in Physiotherapy and Rehabilitation Education

Candidates who will provide the health services of the future should be ready to provide the safe and best health care services. In order to achieve this, it is recommended to use new training programs and methods that will provide similar situations to the working environment in the training of health workers. There are very few studies on the empathy and communication perceptions that creative drama education will create with the patient on physiotherapy and rehabilitation department students. Therefore, this study, the investigators aimed to investigate the perceived effect of communication skills training integrated with creative drama on physiotherapy and rehabilitation students' empathy and communication skills that will develop with the patient.


Eligibility Criteria:
Inclusion Criteria:

* Being willing to take FZT 233 Effective Communication with Creative Drama in Health course in any of the fall or spring semesters.

Exclusion Criteria:

* Desire to take FZT 233 Effective Communication with Creative Drama in Health course at his own request.

  * Not wanting to participate in the study
  * Having a diagnosed psychological disorder and/or receiving psychological treatment